Evaxion Biotech A/S - ADR EVAX

NAS: EVAX | ISIN: US29970R1059 15/01/2026

4,790 USD (-5,34%)

(-5,34%) 15/01/2026

Grafiek Evaxion Biotech A/S - ADR

Grafiek Evaxion Biotech A/S - ADR

1 dag1d -5,34%
1 week1w -5,71%
1 maand1m -21,35%
3 maanden3m -50,10%
6 maanden6m 82,48%
1 jaar1j 42,56%
5 jaar5j -51,57%

Evaxion Biotech A/S - ADR in het nieuws

Toon enkel gratis nieuws

13 januari 2026 · Evaxion expands AI-Immunology™ platform into autoimmune diseases · Persbericht

7 januari 2026 · Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week · Persbericht

19 december 2025 · Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 · Persbericht

6 december 2025 · Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting · Persbericht

20 november 2025 · Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 · Persbericht

12 november 2025 · Evaxion announce 2026 financial calendar · Persbericht

7 november 2025 · Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 · Persbericht

6 november 2025 · Evaxion announces business update and third quarter 2025 financial results · Persbericht

3 november 2025 · Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate · Persbericht

31 oktober 2025 · Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe